Cord blood transplantation using tacrolimus and MMF as GVHD prophylaxis

Cord blood transplantation using tacrolimus and MMF as GVHD prophylaxis - FBMTG CBT16

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025118

Enrollment

Registered

2017-03-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML, ALL, CML, MDS, ML, ATLL

Interventions

Tac 0.02-0.03mg/kg/day day-1 MMF 15mg/kg x 2/day day0-day30

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. available for suitable cord blood stem cells 2. performance status 0-2 3. preserved organ function

Exclusion criteria

Exclusion criteria: 1.not sensitive to chemotherapy 2.complicated infection 3.positive for HBV,HCV,HIV 4.double cancer

Design outcomes

Primary

Measure	Time frame
1 years Overall survival	—

Countries

Japan

Contacts

Public ContactFBMTG Study Office

FBMTG FBMTG Study Office

fbmtg@intmed1.med.kyushu-u.ac.jp092-642-5315

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026